Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
Status:
Completed
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
To see if it is possible to use short-duration tacrolimus after a peripheral blood stem cell
transplant in certain malignancies that are considered difficult to engraft.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins